| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 09/26/2002 | US20020138860 Novel uses of mammalian CCR6 receptors and related reagents |
| 09/26/2002 | US20020138857 Transgenic animals expressing antibodies specific for genes of interest and uses thereof |
| 09/26/2002 | US20020137941 Bicyclic signal transduction inhibitors, compositions containing them & uses thereof |
| 09/26/2002 | US20020137932 Treating autoimmune diseases, Alzheimer's disease, atherosclerosis, osteoporosis, and asthma |
| 09/26/2002 | US20020137907 Novel compounds |
| 09/26/2002 | US20020137892 An isolated peptide transmitter-like receptor polypeptide with specific amino acid sequence or variant which has immunomodulatory, neuromodulatory and endocrinomodulatory activity |
| 09/26/2002 | US20020137801 Administering gossypol; kits to treat patients |
| 09/26/2002 | US20020137789 Anticancer agents |
| 09/26/2002 | US20020137778 Anticancer, antiarthritic, and antiinflammatory agents |
| 09/26/2002 | US20020137757 Quinazolines and therapeutic use thereof |
| 09/26/2002 | US20020137748 Reducing intestinal toxicity of a noncompetitive thymidylate synthase inhibitor by co-administering a folate derivative without blocking therapy; anticancer, antitumore agents |
| 09/26/2002 | US20020137740 CRF (corticotropin releasing factor) antagonists; 4-(2-Chloro-4-methoxyphenyl)-5-methyl-2-(N-(5-ethoxy-carbonyl-2 -methoxyphenyl)-N-propylamino)thiazole for example |
| 09/26/2002 | US20020137739 Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents |
| 09/26/2002 | US20020137714 Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
| 09/26/2002 | US20020137711 Suppression of hematopoietic enzyme; organ grafting |
| 09/26/2002 | US20020137687 Novel compounds that inhibit tryptase activity |
| 09/26/2002 | US20020137686 Inhibitors of the ICE/ced-3 family of cysteine proteases |
| 09/26/2002 | US20020137676 Selective treatment of endothelial somatostatin receptors |
| 09/26/2002 | US20020137202 Diagnosis, treatment, and prevention of disorders associated with a FCTRX nucleic acid, polypeptide, or an antibody specific for it |
| 09/26/2002 | US20020137170 Dual-specificity protein tyrosine phosphatases that dephosphorylate both phosphotyrosine and phosphothreonine/serine residues |
| 09/26/2002 | US20020137138 Modulating serotonin activity |
| 09/26/2002 | US20020137137 Genetic engineering; polypeptides |
| 09/26/2002 | US20020137134 Genetic engineering; glycoproteins |
| 09/26/2002 | US20020137127 Culture product; polypeptides |
| 09/26/2002 | US20020137109 Anticarcinogenic agents;monitoring therapy efficiency |
| 09/26/2002 | US20020136819 Conserved concentrations of cocoa polyphenols by mixing carbohydrate or protein containing ingredients with a polyphenol conserving pretreatment ingredient and then with a cocoa polyphenol |
| 09/26/2002 | US20020136753 Oolong tea extract; antiinflammatories, anti-atopic dermatitis agent or antipsoriatic agent |
| 09/26/2002 | US20020136737 Isolated nucleic acids comprising Listeria dal and dat genes |
| 09/26/2002 | US20020136735 Preparations that potentiate immunogenicity in low immunogenic antigens |
| 09/26/2002 | US20020136729 Combined physical and immunotherapy for cancer |
| 09/26/2002 | US20020136723 Administering methotrexate and an anti-tumor necrosis factor antibody or fragment thereof; rheumatoid arthritis, Crohn's disease, acute and chronic immune diseases |
| 09/26/2002 | US20020136720 Methods of using IMXP-888 and IMXP-888 antagonists |
| 09/26/2002 | US20020136719 For biomedical applications, including biological delivery to humans and animals |
| 09/26/2002 | DE10113366A1 Medicament for treating inflammatory or obstructive respiratory diseases, e.g. asthma or chronic obstructive pulmonary disease, containing synergistic combination of anticholinergic agent and endothelin antagonist |
| 09/26/2002 | CA2852293A1 Attenuated pasteurellaceae bacteria and an anti-bacterial vaccine prepared therefrom |
| 09/26/2002 | CA2469846A1 New interferon beta-like molecules |
| 09/26/2002 | CA2460779A1 Use of gram-negative bacterial membrane fraction for inducing the maturation of dendritic cells |
| 09/26/2002 | CA2445486A1 Patch for transcutaneous immunization |
| 09/26/2002 | CA2445374A1 Process for producing lactic acid oligomer |
| 09/26/2002 | CA2444526A1 Metalloproteinase inhibitors |
| 09/26/2002 | CA2441530A1 Transcutaneous immunostimulation |
| 09/26/2002 | CA2441428A1 Highly purified and crystalline form of harringtonine |
| 09/26/2002 | CA2441155A1 Methods of treating respiratory conditions |
| 09/26/2002 | CA2441152A1 Hormone replacement therapy |
| 09/26/2002 | CA2441111A1 Method for targeting chemical compounds to cells and pharmaceutical compositions used therein |
| 09/26/2002 | CA2441095A1 Modified interferon beta with reduced immunogenicity |
| 09/26/2002 | CA2440956A1 Oligonucleotides for regulating the gene coding for tnf.alpha. and/or genes controlled thereby and use thereof |
| 09/26/2002 | CA2440632A1 Metalloproteinase inhibitors |
| 09/26/2002 | CA2440631A1 Metalloproteinase inhibitors |
| 09/26/2002 | CA2440482A1 Tryptase-inhibitors |
| 09/26/2002 | CA2440475A1 Metalloproteinase inhibitors |
| 09/26/2002 | CA2440272A1 Nucleic acid-associated proteins |
| 09/26/2002 | CA2440264A1 Triazaspiro[5.5]undecane derivative and pharmaceutical composition comprising the same as active ingredient |
| 09/26/2002 | CA2439916A1 Compositions and methods for the treatment and clinical remission of psoriasis |
| 09/26/2002 | CA2439757A1 Methods of using neural thread proteins to treat tumors and other conditions requiring the removal or destruction of cells |
| 09/26/2002 | CA2436911A1 Pyrazolo`4,3-d.pyrimidinone compounds as cgmp pde inhibitors |
| 09/26/2002 | CA2435847A1 Aniline derivatives useful as phosphodiesterase 4 inhibitors |
| 09/26/2002 | CA2435664A1 Ncc2705-the genome of a bifidobacterium |
| 09/25/2002 | EP1243597A2 Receptors for human interleukin-12 |
| 09/25/2002 | EP1243586A1 Phloridzin-rich phenolic fraction and its use as cosmetic, food or nutritional agent |
| 09/25/2002 | EP1243274A2 Methods for inhibiting cancer growth, reducing infection and promoting general health with a fermented soy extract |
| 09/25/2002 | EP1243273A1 Composition comprising a prebiotic for decreasing infammatory process and abnormal activation of non-specific immune parameters |
| 09/25/2002 | EP1243271A1 Nasal drops containing fused pyridazine derivatives |
| 09/25/2002 | EP1243264A2 Inhibition of nitric oxide production by retinoic acid |
| 09/25/2002 | EP1243256A1 Vaccines absorbable by the transmucosal way |
| 09/25/2002 | EP1242608A2 Method of achieving persistent transgene expression |
| 09/25/2002 | EP1242592A2 A molecular switch for regulating mammalian gene expression |
| 09/25/2002 | EP1242590A2 Human lyases and associated proteins |
| 09/25/2002 | EP1242585A1 IDENTIFICATION OF NOVEL SPLICE VARIANTS OF THE HUMAN CATALYTIC SUBUNIT C BETA OF cAMP-DEPENDENT PROTEIN KINASE AND THE USE THEREOF |
| 09/25/2002 | EP1242584A2 Human kinases |
| 09/25/2002 | EP1242583A2 Human oxidoreductase proteins |
| 09/25/2002 | EP1242455A1 N-alkylated peptides having antiangiogenic activity |
| 09/25/2002 | EP1242438A1 Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use |
| 09/25/2002 | EP1242437A2 Novel stromelysin inhibitors |
| 09/25/2002 | EP1242427A1 Novel piperidine and piperazine derivatives |
| 09/25/2002 | EP1242426A1 Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1-piperazinepentanamides as hiv protease inhibitors |
| 09/25/2002 | EP1242421A1 4-[aryl(8-azabicyclo[3.2.1] octan-3-yl)] aminobenzoic acid derivatives |
| 09/25/2002 | EP1242415A1 3-thiazol-4-yl-pyrrolidine derivatives as amp-specific phosphodiesterase inhibitors |
| 09/25/2002 | EP1242413A1 Substituted 1,3,4-oxadiazoles and a method of reducing tnf-alpha levels |
| 09/25/2002 | EP1242410A1 Novel compounds |
| 09/25/2002 | EP1242407A1 Cyclic amp-specific phosphodiesterase inhibitors |
| 09/25/2002 | EP1242406A1 Novel compounds |
| 09/25/2002 | EP1242403A1 2,4-diaminopyrimidine compounds usful as immunosuppressants |
| 09/25/2002 | EP1242400A1 Pyrrolidine derivatives as cyclic amp-specific phosphodiesterase inhibitors |
| 09/25/2002 | EP1242399A1 $g(a)-ARYLETHYLPIPERAZINE DERIVATIVES AS NEUROKININ ANTAGONISTS |
| 09/25/2002 | EP1242396A1 New p2x 7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases |
| 09/25/2002 | EP1242385A1 Cytokine, especially tnf-alpha, inhibitors |
| 09/25/2002 | EP1242382A1 Tricyclic protein kinase inhibitors |
| 09/25/2002 | EP1242371A1 Hydrazone and oxime derivatives of pyrrolidine as amp-specific phosphodiesterase inhibitors |
| 09/25/2002 | EP1242367A1 2-[3-amino-4-(n-hydroxyamino)-succinylamino-acetamides for use as cd23 formation inhibitors |
| 09/25/2002 | EP1242365A1 Acyl pseudodipeptides which carry a functionalised auxiliary arm |
| 09/25/2002 | EP1242364A1 Adamantane derivatives |
| 09/25/2002 | EP1242363A2 Cd45 inhibitors |
| 09/25/2002 | EP1242122A2 Delivery of proteins across polar epithelial cell layers |
| 09/25/2002 | EP1242115A1 Chemically-programmable immunity |
| 09/25/2002 | EP1242109A2 A method for treating viral diseases and other disorders by altering immediate gene expression through administration of peptide t |
| 09/25/2002 | EP1242108A1 Optimized minigenes and peptides encoded thereby |
| 09/25/2002 | EP1242104A2 Process of obtaining thylakoids from plants, pure thylakoids and use thereof |
| 09/25/2002 | EP1242102A2 Asthma/allergy therapy that targets t-lymphocytes and/or eosinophils |
| 09/25/2002 | EP1242086A2 Cd45 inhibitors |